(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 4.03% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.34%.
Zoetis's revenue in 2026 is $9,509,000,000.On average, 21 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,130,654,646,654, with the lowest ZTS revenue forecast at $3,980,990,208,528, and the highest ZTS revenue forecast at $4,351,168,636,722. On average, 21 Wall Street analysts forecast ZTS's revenue for 2027 to be $4,289,122,875,258, with the lowest ZTS revenue forecast at $4,075,735,763,196, and the highest ZTS revenue forecast at $4,632,889,932,018.
In 2028, ZTS is forecast to generate $4,498,736,934,258 in revenue, with the lowest revenue forecast at $4,197,311,917,416 and the highest revenue forecast at $4,877,299,924,812.